NCT05148715View on ClinicalTrials.gov

Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Organ Transplant Failure or RejectionBrain DeathIschemic Reperfusion Injury
Interventions
DRUG

Tacrolimus

Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.

DRUG

Placebo

Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.

Trial Locations (9)

V5Z 1M9

Vancouver General Hospital, Vancouver

V6Z 1Y6

St. Paul's Hospital, Vancouver

H1T 1C8

L'Institut de Cardiologie de Montréal, Montreal

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

H2X 3E4

Centre Hospitalier Universitaire de Montréal, Montreal

H4A 3J1

Centre universitaire de santé McGill (CUSM), Montreal

G1V 4G2

Centre Hospitalier Universitaire de Québec- Université Laval, Québec

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), Québec

J1H 5N4

Centre de recherche CHUS, Sherbrooke

All Listed Sponsors
collaborator

McMaster University

OTHER

lead

Université de Sherbrooke

OTHER